IOM: FDA Needs Post-Market Muscle To Follow Biomarker-Based Approvals
This article was originally published in The Gray Sheet
Executive SummaryCongress should give FDA more authority to require post-market surveillance of medical products approved primarily based on surrogate endpoints, the Institute of Medicine recommends
You may also be interested in...
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.
Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.